Hypera SA (HYPMY)
OTHER OTC:HYPMY
HYPMY Stock Chart & Stats
$4.31
$0.02(0.65%)
At close: 4:00 PM EST
$4.31
$0.02(0.65%)
Day’s Range― - ―
52-Week Range$3.25 - $5.19
Previous CloseN/A
Volume526.00
Average Volume (3M)110.00
Market Cap
$2.97B
Enterprise Value$23.33B
Total Cash (Recent Filing)$1.65B
Total Debt (Recent Filing)$9.34B
Price to Earnings (P/E)12.0
Beta0.69
Next Earnings
Apr 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.73%
Share Statistics
EPS (TTM)0.13
Shares Outstanding633,420,840
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market Cap7.87
Enterprise Value/Revenue3.03
Enterprise Value/Gross Profit5.13
Enterprise Value/Ebitda10.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Margins And ProfitabilitySustained gross and net margins near 58% and 16% reflect durable pricing power and cost control in consumer health and generics. High margins support steady operating earnings, fund reinvestment and dividends, and cushion results against modest volume or cost swings over months.
Stronger Cash GenerationRecord operational cash flow and completed working-capital optimization materially improve liquidity and lower leverage. This strengthens the company’s ability to fund capex, pay shareholders and reduce net debt, making operations more resilient across the medium term.
Brand, Scale And Vertical IntegrationEstablished OTC brands, wide distribution and vertical manufacturing integration create sustainable competitive advantages: lower unit costs, faster product launches and strong retail placement, which support market share retention and margin durability over the coming quarters.
Bears Say
Weak Cash ConversionSubpar cash conversion versus accounting profits signals persistent working-capital drag or higher cash taxes/interest/capex. That constrains free cash available for growth, M&A or sustainable shareholder returns and increases sensitivity to cyclical working-capital swings.
Cooling Returns On EquityDeclining ROE indicates the business is generating lower returns from equity capital than prior years, reducing capital efficiency. Persistently lower ROE can limit reinvestment upside and pressure long-term shareholder returns if not reversed by structural growth or margin expansion.
Regulatory Delays Hit PipelineSlower ANVISA approvals delay new product rollouts and revenue diversification, extending payback timelines on R&D and marketing investments. Prolonged regulatory friction can erode competitive momentum in key categories and magnify dependence on legacy brands.
Hypera SA News
HYPMY FAQ
What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $3.25 and its highest was $5.19 in the past 12 months.
What is Hypera SA’s market cap?
Hypera SA’s market cap is $2.97B.
When is Hypera SA’s upcoming earnings report date?
Hypera SA’s upcoming earnings report date is Apr 28, 2026 which is in 31 days.
How were Hypera SA’s earnings last quarter?
Hypera SA released its earnings results on Mar 12, 2026. The company reported $0.131 earnings per share for the quarter, beating the consensus estimate of N/A by $0.131.
Is Hypera SA overvalued?
According to Wall Street analysts Hypera SA’s price is currently Overvalued.
Does Hypera SA pay dividends?
Hypera SA pays a Notavailable dividend of $0.036 which represents an annual dividend yield of 4.73%. See more information on Hypera SA dividends here
What is Hypera SA’s EPS estimate?
Hypera SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypera SA have?
Hypera SA has 633,420,840 shares outstanding.
What happened to Hypera SA’s price movement after its last earnings report?
Hypera SA reported an EPS of $0.131 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.052%.
Which hedge fund is a major shareholder of Hypera SA?
Currently, no hedge funds are holding shares in HYPMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hypera SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.89%
12-Months-Change
Fundamentals
Return on Equity
9.86%
Trailing 12-Months
Asset Growth
16.29%
Trailing 12-Months
Company Description
Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
HYPMY Company Deck
HYPMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.View all HYPMY earnings summariesTechnical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---